Upadacitinib Leads in Efficacy: A Bayesian Network Meta‐Analysis of Four JAK Inhibitors in Moderate‐To‐Severe Atopic Dermatitis
International Journal of Dermatology · 2026
DOI: 10.1111/ijd.70228 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift International Journal of Dermatology, 2026. Verfasst von Arya Babul und 4 weiteren Autor:innen. Beteiligte Einrichtung: West Career & Technical Academy, and Society for Awareness of Neglected Diseases, Las Vegas, Nevada, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 81 Literaturangaben.
Abstract (Originalsprache)
Background
Janus kinase inhibitors (JAKis) have revolutionized the management of moderate‐to‐severe atopic dermatitis (AD). Although agents approved by the United States Food and Drug Administration (FDA), such as upadacitinib and abrocitinib, are widely used, and baricitinib and ivarmacitinib are under investigation, direct head‐to‐head randomized clinical trials (RCTs) comparing these agents are lacking.
Objective
Our aim was to rank the short‐term efficacy of four oral JAKis, upadacitinib (15/30 mg), abrocitinib (100/200 mg), baricitinib (2/4 mg), and ivarmacitinib (4/8 mg), in moderate‐to‐severe AD using a Bayesian Network Meta‐Analysis (BNMA).
Methods
Conducted per PRISMA 2020 guidelines and registered in PROSPERO (CRD420251116775), this study systematically reviewed phase 2 and 3 RCTs evaluating JAKi monotherapy in adults with moderate‐to‐severe AD. Primary endpoints included: (1) ≥ 75% improvement in Eczema Area and Severity Index (EASI‐75), (2) Investigator's Global Assessment (IGA‐ AD 0/1), and (3) ≥ 4‐point reduction in itch numeric rating scale (Itch NRS) at 12–16 weeks. Bayesian hierarchical modeling estimated odds ratios (ORs) with 95% credible intervals (CrIs), and surface under the cumulative ranking curve (SUCRA) probabilities defined the treatment hierarchy.
Results
Nine RCTs ( n = 4261) were included. Upadacitinib 30 mg demonstrated the greatest efficacy across all endpoints, EASI‐75 (OR = 12.3; 95% CrI 7.9–18.7), IGA‐ AD 0/1 (OR = 18.9; 95% CrI 12.0–29.7), and Itch NRS (OR = 11.1; 95% CrI 7.2–17.5), followed by upadacitinib 15 mg, abrocitinib 200 mg, and ivarmacitinib 8 mg. Baricitinib 2 mg and 4 mg consistently ranked lowest. SUCRA values confirmed upadacitinib 30 mg as the top performer (97%–98%).
Conclusion
Among oral JAKis, upadacitinib 30 mg, followed by upadacitinib 15 mg, achieved the most consistent short‐term efficacy, providing superior skin clearance and itch relief. Abrocitinib 200 mg and ivarmacitinib 8 mg showed intermediate benefits, whereas baricitinib displayed modest effects. These findings support a provisional efficacy preference for upadacitinib in managing moderate‐to‐severe AD unresponsive to biologic or topical therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- West Career & Technical Academy, and Society for Awareness of Neglected Diseases, Las Vegas, Nevada, USA.
- General, Surgical, and Cosmetic Dermatology, Thomas Dermatology, Las Vegas, Nevada, USA.
- Genomics Department, Chinese Academy of Tropical Agriculture Sciences, Sanya, China.
- Cinergen LLC, Las Vegas, Nevada, USA.
ORCID-Profile: Arya Babul, Devina Mehta, Yssra Soliman, Momina Hussain, Najib Babul
Zitieren
APA
Babul, A., Mehta, D., Soliman, Y., Hussain, M., & Babul, N. (2026). Upadacitinib Leads in Efficacy: A Bayesian Network Meta‐Analysis of Four JAK Inhibitors in Moderate‐To‐Severe Atopic Dermatitis. International Journal of Dermatology. https://doi.org/10.1111/ijd.70228
Vancouver
Babul A, Mehta D, Soliman Y, Hussain M, Babul N. Upadacitinib Leads in Efficacy: A Bayesian Network Meta‐Analysis of Four JAK Inhibitors in Moderate‐To‐Severe Atopic Dermatitis. International Journal of Dermatology. 2026. doi:10.1111/ijd.70228
BibTeX
@article{Babul2026,
author = {Babul, Arya and Mehta, Devina and Soliman, Yssra and Hussain, Momina and Babul, Najib},
title = {Upadacitinib Leads in Efficacy: A Bayesian Network Meta‐Analysis of Four JAK Inhibitors in Moderate‐To‐Severe Atopic Dermatitis},
journal = {International Journal of Dermatology},
year = {2026},
doi = {10.1111/ijd.70228}
}
EUVIMED